Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
- Hotz, Christian Center for Integrated Protein Science Munich (CIPSM)
- Bourquin, Carole Center for Integrated Protein Science Munich (CIPSM)
-
2011
Published in:
- Oncoimmunology. - 2012, vol. 1, no. 2, p. 227-228
English
Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.
- Faculty
- Faculté des sciences et de médecine
- Department
- Département de Médecine
- Language
-
- English
- Classification
- Biological sciences
- License
- License undefined
- Identifiers
-
- RERO DOC 30504
- DOI 10.4161/onci.1.2.18169
- Persistent URL
- https://folia.unifr.ch/unifr/documents/302510
Statistics
Document views: 37
File downloads:
- bou_sci.pdf: 61